AbbVie(US:ABBV) Prnewswire·2024-10-02 12:00Core Insights - Allergan Aesthetics has announced the national availability of JUVÉDERM® VOLUMA® XC for treating moderate to severe temple hollowing, following its FDA approval in March 2024, making it the first and only hyaluronic acid filler approved for this indication [1][2][4] Product Launch and Training - The company has implemented a robust training protocol for providers to ensure they are well-versed in the science of injecting the temple area, emphasizing the importance of comprehensive training for all Allergan Aesthetics products [2][4] - JUVÉDERM® VOLUMA® XC is part of the JUVÉDERM® Collection, which includes six specifically formulated hyaluronic acid fillers designed to meet various aesthetic goals [2][4] Patient Satisfaction and Efficacy - Approximately 90% of patients reported satisfaction with the natural look and feel of their temples three months post-treatment, and over 85% noted overall aesthetic improvement one month after treatment, with results lasting up to 13 months [2][4] - A high satisfaction rate of 98% of patients treated in the temple area would recommend the treatment to a friend, indicating strong consumer confidence in the product [2][4] Safety and Approval - JUVÉDERM® VOLUMA® XC has an established safety profile and is approved for adults of all Fitzpatrick skin types over 21 years of age, ensuring broad applicability [2][4] - The product is designed to create a balanced and youthful appearance, making it an ideal choice for patients seeking subtle, natural-looking results [2][4] Loyalty Program and Consumer Education - Patients interested in JUVÉDERM® VOLUMA® XC for temple hollowing are encouraged to enroll in Allē, Allergan Aesthetics' loyalty rewards program, which serves over seven million members across approximately 30,000 practices [3][4] - Allē aims to educate consumers about aesthetic treatments and simplify office operations for practices, enhancing the overall treatment journey for patients [3][4]